Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $54.5 million.

  • Corcept Therapeutics' Free Cash Flow fell 2397.08% to $54.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $163.1 million, marking a year-over-year increase of 1479.73%. This contributed to the annual value of $195.9 million for FY2024, which is 5436.96% up from last year.
  • As of Q3 2025, Corcept Therapeutics' Free Cash Flow stood at $54.5 million, which was down 2397.08% from $43.9 million recorded in Q2 2025.
  • Corcept Therapeutics' Free Cash Flow's 5-year high stood at $71.7 million during Q3 2024, with a 5-year trough of $5.0 million in Q1 2025.
  • For the 5-year period, Corcept Therapeutics' Free Cash Flow averaged around $37.6 million, with its median value being $40.8 million (2024).
  • Its Free Cash Flow has fluctuated over the past 5 years, first plummeted by 8235.15% in 2023, then soared by 91425.17% in 2024.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Free Cash Flow stood at $49.4 million in 2021, then tumbled by 32.42% to $33.4 million in 2022, then tumbled by 82.35% to $5.9 million in 2023, then soared by 914.25% to $59.7 million in 2024, then decreased by 8.76% to $54.5 million in 2025.
  • Its Free Cash Flow was $54.5 million in Q3 2025, compared to $43.9 million in Q2 2025 and $5.0 million in Q1 2025.